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BACKGROUND: CD4+ T-cell count External Quality Assessment 
program is important for the evaluation of performance of CD4 
count laboratories. The aim of this study was to assess the quality 
of CD4count laboratory performance using in-house Proficiency 
testing panels that perform routineCD4 counts in Addis Ababa, 
Ethiopia, 2013/14. 
METHODS: Participating laboratories were 20, 23 and 25 in trials 
1, 2 and 3, respectively. In-house prepared fresh whole blood 
samples both with “normal” and “low” CD4 values were sent to 
participating laboratories. Percentage and absolute counts of 
CD4+ T-lymphocytes were done using their routine procedures. 
Data were analyzed for each trial including trimmed mean, 
standard deviation (SD), percent coefficient of variation (%CV), 
residual, and standard deviation index (SDI) values for both 
absolute counts and percentages of CD4+ lymphocytes (%CD4). 
RESULTS: Most participating laboratories produced results that 
were within 2SD of the mean. Average inter-laboratory precision 
(trimmed %CV) was 10.87% and 5.14% for CD4 absolute counts 
and %CD4, respectively. For normal material, the trimmed mean 
%CV was 9.59% and3.23% for CD4 absolute counts and %CD4, 
respectively. For low material, the trimmed mean % CV was 
12.15% and 7.05% for CD4 absolute counts and %CD4 
respectively. BDFACSCount™ users showed the best accuracy 
and precision as evidenced by longitudinal analysis. 
CONCLUSION: This study was found to help facilities in early 
identifying their gaps with regard to their CD4 count performance 
and in avoiding the challenges encountered during participation 
in external EQA providers like the high cost, transportation 
problem, feedback delay and CD4laboratory coverage. 
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External quality assessment (EQA) is an 
evaluation of the performance of a number of 
laboratories by an outside organization on 
specially supplied proficiency testing (PT) panels 
(1,2). EQA scheme monitors the performance of 
each laboratory over time and identifies those 
laboratories that require training or corrective 
action to improve their performance (3,4). One of 
the best ways for a laboratory to monitor its 
performance, against both its own requirements 
and the performance of other laboratories, is to 
participate regularly in an EQA scheme (5-6). 
EQA programs operate through a 
combination of three approaches that include 
participation in external PT programs, 
supervisory site visits by external experts, and re-
testing a subset of specimens in another 
competent laboratory or site at a higher level 
(8,9). There are several well recognized 
international immune monitoring EQA schemes 
available for CD4 testing. In Africa, few 
laboratories participate in international EQA 
schemes in comparison with their international 
counterparts (10,11). 
In Africa, the proportion of countries with a 
national quality assurance (QA) program for HIV 
has increased from 51% in 2003 to 61% in 2007, 
but participation was limited mainly to reference 
laboratories (12). African regional external 
quality assessment scheme (AFREQAS) (13) was 
introduced in 2002 in support of this need but this 
was also mainly limited to reference laboratories 
(14,15). HIV/AIDS has become a major public 
health concern, leading the government of 
Ethiopia to declare a public health emergency in 
2002. In 2011, adult HIV/AIDS prevalence in 
Ethiopia was estimated to be 1.5% (16). 
Accurate absolute CD4+T-cell counts, as 
well as their percentage values are required for 
the following purpose:(1) to assess the degree of 
immune deterioration and rate of progression 
towards AIDS (defined as a CD4+ lymphocyte 
count of< 0.2 x 109 /liter or < 14%),(2) to group 
HIV sero-positive patients into cohorts according 
to their baseline CD4+T-counts before starting 
treatment(3) to determine the appropriate time for 
prophylaxis of opportunistic infections, and (4) to 
monitor the efficacy of antiretroviral and/or 
interleukin 2 (IL-2) treatment and candidate 
vaccines(17-20). Therefore, there is clinical need 
for accurate and precise enumeration of CD4+ T-
cells (21-22). 
In developing countries, rigorous QA 
practices for HIV diagnostic and follow-up 
testing are not routinely followed to ensure 
reliability of results and a safe work environment. 
Considering the nature and complexity of EQA to 
include the need for follow-up supervision and to 
resolve non-conformances, it is recommended 
that countries set up functional EQA program to 
be coordinated at national level with the capacity 
to either produce or procure PT panels to 
distribute to other laboratories (23-25). 
According to Brando et al, EQA programs 
for clinical cell analysis should not be doomed to 
remain monopolized by a few major providers 
worldwide even if there are challenges. One of 
the key challenges in running PT program has 
been that of the cost and distribution to include 
the issues of maintaining cold chain, packaging 
and shipment with maximum safety to laboratory 
staff and people involved in the shipment exercise 
(25,26). 
In Ethiopia, specifically in Addis Ababa, 
there is extensive expansion of public and private 
ART sites for the treatment and monitoring of 
HIV infected patients. The two most commonly 
available and used flow cytometry machines in 
Ethiopia for ART initiation and monitoring 
areBD FACSCount, which is available almost in 
all ART laboratories and BD FACSCalibur that is 
available at a referral level and some private 
laboratories (27). 
In Ethiopia, different ART CD4 count 
laboratories participate in EQA programs through 
Quality Assessment Scheme International (QASI) 
(that is coordinated by the Ethiopian Health and 
Nutrition Research Institute (EHNRI)) and/or 
AFREQAS that send-out lyophilized materials. 
Since the imported lyophilized panels need 
reconstitution upon supplier’s instructions, this 
process reduces the commutability of the 
materials and feedback takes long time (above six 
months) after result submission. Other problems 
associated with participation include the high cost 
of EQA schemes, logistical problems with sample 
transport to testing sites, and lack of infrastructure 
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and computers to enter data onto websites for 
submission of results. In addition, international 
EQA schemes are frequently commercial 
investments, and their focus may not necessarily 
be the development of quality laboratory capacity 
building in resource-poor settings (1,11,13). 
Thus, the objective of this study was to 
assess the quality of CD4 + count laboratory 
performance using in-house PT panels in Addis 
Ababa, Ethiopia. 
 
MATERIALS AND METHODS 
 
Study participants: Public, non-governmental 
organization, and private CD4 count laboratories 
were included in the study based on their 
provision of routine CD4 testing voluntarily. The 
study was conducted in Addis Ababa, Ethiopia, 
from December 2013 to July 2014 after ethical 
clearance was obtained from the School of 
Medical Laboratory Sciences, College of Health 
Sciences, Addis Ababa University and Addis 
Ababa City Administration Health Bureau. 
Relevant data like flow cytometer and antibody 
panel used, internal quality control and pipetting 
method used, pipette calibration, bead product 
used, and work load of each laboratories were 
gathered by using preliminary structured 
questionnaire. Three trials were carried out, and 
out of 27 laboratories, 20, 23 and 25 were 
participated in trials 1, 2 and 3, respectively. 
Preparation of EQA material for shipment: 
The preparation was done at Medical Biotech 
Laboratory (MBL). MBL participates in CD4 
EQA scheme with digital PT Canada (organized 
through EHNRI) and in AFREQAS (organized 
through National Health Laboratory Service, 
Johannesburg, South Africa) quarterly and every 
two monthly respectively with excellent 
performance. In-house PT material was prepared 
by drawing predetermined CD4 value and 
HBsAg, HCV, HIV-1 and HIV-2 negative fresh 
whole blood obtained from one donor in to 4ml 
K3-EDTA BD vacutainer tubes (8-12 tubes). The 
collected blood was mixed thoroughly in 
automated hematology-mixer machine to insure 
homogeneity of the materials. Once mixed, it was 
then pooled into a large sterile container with 50 
ml volume capacity (Costar, Corning, Inc., 
Corning, NY) and gently mixed again to ensure 
uniformity of pooled samples. The above blood 
was separated into two samples (sample-A and -
B) to prepare the normal (sample-A) and low 
(sample-B) EQA materials. 
Normal EQA material was prepared in such 
a way that it coincides with Ethiopian CD4 T-
cellcounts (753±227 cells/µl for adult male) (28). 
Low EQA material was prepared by continuous 
dilution of sample-B using phosphate buffer 
saline (PBS) until desirable low CD4 count was 
attained (100-300 cells/µl range). Similar 
preparation of fresh whole blood for CD4 EQ 
Ascheme was reported by Kunkl et al, in 2002 
(29). Normal and low materials were packed 
according to WHO guidelines before dispatch 
time (30 – 33). Each batch of EQA blood was 
evaluated to ensure that immuno-phenotypic 
characteristics have been maintained during 
handling and transportation. 
Dispatch of CD4 EQA material: All shipments 
included in-house prepared PT material and its 
handling and running instruction sheets, data 
report form with unique participant identifier, 
clear instructions of the date of submission 
deadline, and safety information. It was 
personally delivered by the principal investigator 
at the same day of blood collection to each 
participant throughout the 3 trials. On the 
dispatch dates, the material was sent in plastic 
transport bag box to maintain optimal temperature 
by avoiding direct sunlight (at ambient 
temperature (18-22°)). All participants received 
their samples within 1-8 hours of EQA material 
dispense. All communications were mainly based 
on telephone and personal contact before and 
during all the dispatch dates. 
Statistical analysis of trial data: Microsoft 
ExcelTM, sigma plot version 12.3, and Graph 
Pad® Prism version 5, were used to capture data 
and to generate statistics, tables, graphs, letters 
and feedback to all participating laboratories. 
Each participant’s data was analyzed 
according to international practice (5,6,10,13). On 
receipt of all participant data for each trial, CD4 
absolute counts and CD4% of Lymphocyte values 
were entered into Microsoft ExcelTM. The mean, 
standard deviation (SD = [√Σ(X1 - X) 2 /(n -1)] ), 
and coefficient of variation (%CV = SD/Mean 
x100) were calculated automatically by the 
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Microsoft ExcelTM, and a ±2SD limit determined 
for both CD4 parameters (untrimmed pooled 
data). Results that fell outside the ±2SD limit 
were identified and removed as outliers and pool 
data re-analyzed to calculate pooled trimmed 
mean, pooled trimmed SD, and pooled trimmed 
%CV. Each participant’s ‘‘Residual’’ expressed 
in CD4 cells/µl or CD4% (equal to participant’s 
submitted CD4 absolute or CD4% result minus 
the trimmed pool mean result) and the standard 
deviation index (SDI) (equal to participant’s 
‘‘Residual’’ divided by SD of the trimmed mean, 
expressed as a ratio) were calculated and 
compared to the pooled trimmed results to 
indicate bias(31). The overall participation 
response rates (RR) were calculated as the 
(number of submitted results) divided by (the 
number of shipped samples). Non-return rates 
(NR) were calculated as the (number of 
laboratories that did not return results) divided by 
the (number of shipped samples). Percentage of 
outlying results or ‘‘Outlier Rate’’ (OR) was 
calculated as (number of sites with SD >2.0 of the 
trimmed pool mean) divided by the (number of 
submitted results). All rates were expressed as 
percentages. 
Participants were informed about the 
procedure of feedback and identifying problems 
to assist laboratories with trouble shooting. Those 
participants whose results were outside the ±2SD 
of the trimmed pool mean were contacted 
immediately to effect corrective action timely and 
were not allowed to resubmit corrected results. 
This was based on advice on different 
technologies and guidelines for equipment 
maintenance and regular service of instruments. 
Participant laboratories were also advised to use a 
Levey-Jennings wall chart to plot and monitor 
their performance over time. 
 
Assessment of longitudinal performance of 
individual participants: Individual SDI 
performance of laboratories was monitored 
longitudinally by graphically representing the 
SDI values versus trial number on a radar graph 
(13,21). These radar plots enabled visual 
representation of the accuracy and precision of 
CD4 absolute counts and CD4%of Lymphocytes 
for individual participants (13,20). 
 
Statistical analysis of overall precision of BD 
FACSCount™ users: For each trial, submitted 
results for both absolute counts and CD4% of 
Lymphocytes was pooled and mean, SD and 
%CV calculated to assess their accuracy and 
precision. The Longitudinal precision was 
analyzed (%CV over the 3 trials) for both 
absolute counts and CD4% of Lymphocytes. 
These results were plotted on scatter plots using 
Graph Pad Software. To assess the longitudinal 
accuracy and precision of BD FACSCount™ 
users, the standardized individual laboratory SDI 
values were pooled across the 3 trials. Thus a 
mean (SDI) was calculated per trial, and Radar 
plots were used to show the mean of the pooled 
SDI values plotted trial by trial. Also, it was 
plotted in Gaussian distribution plot. In this 
pooled SDI analysis, the calculated mean of the 
pooled SDI reflects longitudinal accuracy. The 
SD of the mean of the SDI reflects longitudinal 
precision. In this analysis, ideal accuracy mean 
(SDI) values should be expected to be 0.0 with an 
expected range of -1 to +1. Ideal precision SD 
(Mean SDI) values should be expected to be 1.0 




Participant laboratories: The number of 
participants in the study increased from 20 to 25 
laboratories (almost all laboratories in Addis 
Ababa) by trial 3, representing an average 
monthly growth rate of 11.9%. The study issued 3 
trials, equating to 136 in-house PT panels of 
which 68were “normal” and 68 “low” CD4 value 
materials. The response rate was 100%. 
 
Performance of all participant laboratories: 
Over the 3 trials, participant laboratories showed 
an average between laboratory 
precision/reproducibility (upper acceptable limit 
is 10% CV) for absolute CD4 counting of10.87% 
CV, ranging between 7.88% (Trial 1A) to 15.49% 
(Trial 3B). The trimmed mean between laboratory 
precision for CD4% of lymphocytes was 5.14% 
CV, ranging between 2.25% (Trial 1A) to 10.44% 
(Trial 2B). 
For normal CD4 value material, the trimmed 
mean %CV was 9.59% and 3.23% for 
CD4absolute counts and CD4% of Lymphocytes, 
respectively. For low CD4 value material, the 
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trimmed mean %CV for CD4 absolute counts and 
CD4% of lymphocytes was 12.15% and7.05%, 
respectively. Overall, the participating 
laboratories showed relatively poorer precision 
(%CV) and accuracy with “low” material than 
with “normal” material for both CD4 absolute 
counts and CD4% of lymphocytes. In trials 1 and 
2 only, 2 results (from trial 2) were out of ±2SD 
with the normal material, but 4 results (three from 
trial 2 and one from trial 1) were out of ±2SD 
from low material. In the same manner, one result 
from normal material and 2 results from low 
material were out of ± 2SD in trial 3 as well. 
Participant performance was characterized as 
excellent and good based on the number of 
outliers and non-submissions. Excellent 
performers had neither outliers nor non-
submissions during their time of participation. 
Good performers had 2 or less outliers/non-
submissions for the duration of their participation. 
A similar grouping criterion was used elsewhere 
(1,13). 
Overall, 81.48% of the participants reporting 
CD4 absolute counts and 76.92% of participants 
reporting CD4% of lymphocyte showed excellent 
serial continued performance across 3 trials. Here, 
the methodologies used comprised of BD 
FACSCount™ users, PimaTMCD4, 
BDFACSCalibur™, and a single laboratory using 
PartecCy Flow counter test. A second group of 
users defined as good performers comprised 
further 18.52% of participants reporting 
CD4absolute counts and 23.08% participants 
reporting CD4% of lymphocyte. The 
methodologies here are mainly Pima TM CD4. In 
the group with “good performers”, 40% of them 
showed improvement in the third trial as opposed 
to consecutive outliers. 
 
Precision of laboratories using the same CD4 
methodology: During the three trials, BD 
FACSCount™, PimaTMCD4, BD 
FACSCalibur™, and PartecCy Flow counter were 
performed as a single platform test but except BD 
FACSCount™, their numbers were insufficient 
(less than 10) for statistical analysis as a group. 
As a result, they were excluded from group 
comparison, but their performance was assessed 
together with all participants. The numbers of BD 
FACSCount™, BD FACSCalibur™ and PimaTM 
CD4 users were 17, 4 and 4, respectively by the 
end of the third trial, and Partec® methodology 
was a single participant in the first two trials. The 
average number of BD FACSCount™ users was 
16 laboratories. In trial 2, 13.78% CV was 
recorded which was relatively poor, which was 
due to a single outlier where one participant 
reported a CD4 absolute count of 386 cells/µl for 
low material. On removing this outlying result, 
(Grubbs’ test of outlier applied), the overall 
trimmed mean for all technology users was 
265.82 with a %CV reduced by 3.12% CV.BD 
FACSCount™ methodology. 
Across the 3 trials, performance of BD 
FACSCount™ users (comprising 72.67% of 
participants) for CD4 absolute counts showed 
consistently good performance. The overall mean 
precision (%CV) was 9.13% and 5.15% for 
absolute CD4 counts and CD4% of lymphocytes, 
respectively. For normal CD4 value material, a 
trimmed mean %CV of 8.58% and 3.07% was 
recorded for absolute CD4 count and CD4% of 
lymphocytes, respectively. For low CD4 value 
material, the trimmed mean %CV was 9.67% and 
7.22% for absolute CD4 count and CD4% of 
lymphocytes, respectively. 
To assess longitudinal accuracy and 
precision, the standardized individual laboratory 
SDI values were pooled across 3 trials and a 
mean (SDI) was calculated per trial (Figures 1-3). 
Pooled SDI data reflecting longitudinal accuracy 
and precision across 3 trials showed that 
laboratories using BD FACSCount™ could 
consistently generate accurate and precise 
absoluteCD4 counts irrespective of whether 
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Figure 1: Radar plots illustrating the longitudinal performance (SDI) of BD FACSCount™ methodology 
across the three trials  
 
In the above figure, the X-Axis reflects SDI 
performance on a scale of -3 to +3 where 
acceptable range is -2.0 to +2.0. Y-Axis indicates 
the consecutive trial. SDI values were plotted for 
both the absolute CD4 count (Green line) and 
CD4% of lymphocyte values (totally obscured by 
the target line because they have same value i.e. 
zero). As a result; it is hidden. 
On low CD4 value material, longitudinal 
follow-up showed slightly poorer accuracy (mean 
SDI) and precision than with normal CD4 value 
material. This, however, did not impact on the 
overall good performance of this methodology on 
the study. Only one trial showed relatively poorer 
precision (Trial 2). This was due to one outlier 
where one participant reported CD4%lymphocyte 
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Figure 2: Gaussian distribution curves showing longitudinal accuracy (mean SDI, Ai and B i) and 
precision (SD of mean SDI), Aii and B ii) for BDS FACSCount™ users for CD4 absolute counts.  
 
In figure 2, Green areas represent the acceptable 
limits for both Mean SDI and SD of (mean SDI) 
values, while yellow areas indicate values outside 
the acceptable limits. Ideal values for both mean 
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Figure 3: Gaussian distribution curves showing longitudinal accuracy (mean SDI, Ai and Bi) andprecision 
(SD of mean SDI), Aii and B ii) for BD FACSCount™ users for CD4% of lymphocyte 
 
In figure 3, greenare as represent the acceptable 
limits for both Mean SDI and SD of (mean SDI) 
values, while yellow areas indicate values outside 
the acceptable limits. Ideal values for both mean 
SDI (0) and SD of (mean SDI)(1) are indicated. 
 
Investigation of laboratories with outlying 
results: An outlier was defined as a submitted 
result falling outside of ±2SD of the trimmed pool 
mean. The percentage outlier rate (OR) of 
absolute CD4 counts and CD4% of lymphocytes 
for all trials were 4.3% and 4.1% respectively.  
 
 
The percentage OR of normal CD4 EQA material 
was 1.4%and 5.3% for absolute counts and 
CD4% of Lymphocyte respectively and that of 
low CD4 EQA material was 7.2% and 2.8% for 
absolute counts and CD4% of Lymphocyte 
respectively. OverallBD FACSCount™ and BD 
FACSCalibur users showed the least outliers 
across 3 trials with an average of<5% and <7% 
respectively. The PimaTMCD4 user group showed 
higher outliers across the 3 trials with an average 
of<17%. The single Partec® user laboratory had 
no outliers and non-submission of results across 
the first 2 trials. 
Accuracy
Normal Value Material
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Effects of feedback for remedial action: 
Feedback was individualized and remedial input 
given was specific to the problem of the 
CD4method used by that site. These include 
appropriate feedback and advice on corrective 
action. Outliers on CD4 absolute counts and 
CD4% of Lymphocytes were noted on Trial 1 and 
the laboratories were subsequently contacted to 
investigate the inaccuracy and imprecision of 
pipetting through the validation of pipettes based 
on their respective methods user’s guide. With 
corrective action feedback to these laboratories, 





During the 3 trials, the overall participation rate 
was excellent with average 93.1%. The average 
response rate was 100%. Overall, reasons for 
100% response rate were due to consistent 
information exchange between the study 
coordinator and managers of participant 
laboratories. 
The other 6.9% of potential laboratories 
were not participated. This was due to poorly 
developed flowcytometry maintenance, lack of 
BD FACSCount Reagents, lack of supplier and 
vendor availability for support and maintenance 
of equipment, unreliable power supplies, poorly 
developed custom clearance and infrastructure. 
The average precision of all participant 
laboratories across the 3 trials was 10.87 and 
5.14%CV for absolute CD4 counts and CD4% of 
Lymphocytes, respectively. This performance is 
better than the overall precision (%CV) reported 
on the AFREQA scheme across 20 trials of 
11.9CV% for absolute CD4 counts and 10.7 
CV% for CD4% of Lymphocytes (13). This can 
be explained by the fact that in-house PT panels 
were shipped within the same day of preparation 
to participants but in AFREQAS transportation of 
EQA materials was taken longer time. As a result, 
the commutability of materials can be reduced 
through time and temperature fluctuation. In 
AFREQAS, the huge numbers of participants 
used single and dual platform technology that 
may increase the %CV, but in this study, all 
participants were used only single platform 
technology. 
Another study done by Lopez et al reported 
similar improved precision mean CV of less than 
10% (7). It is a little bit higher than the overall 
precision %CV reported on the EQA Program in 
Thailand of less than 8% for CD4 T-lymphocytes 
(20). According to the information obtained from 
preliminary structured questionnaire and data 
report form, most of the participants do not 
calibrate their pipettes and in a few laboratories, 
mismatched reagent lot number (ID) and control 
run reagent lot number (ID) was found. This is 
probably the reason for the increased % CV. With 
the “normal” and “low” CD4 value material, 
similar findings were reported in other studies 
(13,18), with overall slightly poorer precision 
with “low” count material than “normal” count 
material amongst participants. 
Overall accuracy and precision of BD 
FACSCount™ users was excellent as evidenced 
by the tight Mean SDI and narrow SD (of the 
Mean SDI) noted in the longitudinal analysis 
(Figure 2,3). This excellent performance was 
maintained irrespective of whether “normal” or 
“low” material was used and a mean %CV of less 
than 10% CV was recorded for both normal and 
lowCD4 absolute counts and CD4% of 
lymphocytes across 3 trials. A similar study was 
conducted in Thailand (13,20). One error, 
common to several BD FACSCount™ users, was 
related to incorrect pipetting and use of poorly 
calibrated pipettes, also reported elsewhere 
(7,13). 
Overall, the performance of the CD4 
laboratories in Addis Ababa is similar to that 
reported elsewhere (7,13,15,20). However, few of 
the CD4 methodologies, specifically one 
PimaTMCD4, showed inconsistent results between 
trials. The probable reason may be the difficulty 
to evaluate as group users due to their small 
number. In addition, these technologies were new 
and three of them were incorporated at the second 
trial of the study and were allowed to give service 
for patients as they purchased without in-house 
validation. Other difficulties with new coming 
methods are: laboratory technicians were not 
trained about the usage and maintenance of the 
machines rather deputies of the seller (vendor) 
company install it in the laboratory and show 
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them how they perform at the first time of 
purchasing. 
The findings of this study showed that those 
laboratories which submitted results with outliers 
in trial 1 were consistently reported with no 
outliers in the subsequent trials after appropriate 
feedback and advice was given. Thus, it is 
reasoned that the longer the laboratories 
participating in the EQA trial, the better the 
performance of these laboratories. There are some 
limitations to this study. Firstly, unlike that of 
other CD4 EQA schemes done elsewhere with 
multiple numbers of trials, this study was done in 
a short period of time. This was due to lack of 
sponsors since it needed a huge amount of budget 
for its continuity and sustainability. Secondly, 
corrective action feedback was solely based on 
advice and provision of guidelines, but training 
was not given even if many requests were 
reported from participating laboratories. This was 
due to limited inputs and lack of sponsorship. 
To conclude, the pilot-feasibility of 
preparation of in-house PT panel for CD4 
enumeration was assessed and found to be 
satisfactory. Our study was helpful in early 
identifying of participants’ gaps with regard to 
their CD4 count performance. This study may be 
considered as a significant advancement for 
CD4count laboratories in Addis Ababa and at 
national level for its use as a baseline, since no 
such study was available previously. Above all, 
this study is helpful to avoid external dependency 
on CD4 EQA. This is because participation in 
externally provided EQA scheme is difficult in 
terms of cost, transportation, coverage of all 
laboratories, on-time feedback and 
communication. As a result, this study has been 
widely accepted by participant laboratories. 
In Ethiopia, there is no established national 
CD4 EQA scheme. As a result, it is best to 
expand and continue this study as a program 
using in-house prepared PT panels at national 
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